Complete Filing Data
LB PHARMACEUTICALS INC reported Stockholders Equity of $301.31 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean LB PHARMACEUTICALS INC did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income Loss | -$25.2M | -$63.1M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $57.0K | -$163.0K |
| Research And Development Expense | $16.7M | $51.2M |
| Operating Expenses | $30.4M | $64.8M |
| Nonoperating Income Expense | $5.2M | $1.7M |
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | $119.0K | $955.0K |
| Income Tax Expense Benefit | $1.0K | $1.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$25.2M | -$63.1M |
| General And Administrative Expense | $13.7M | $13.7M |
| Comprehensive Income Net Of Tax | -$25.1M | -$63.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$3.6M | -$4.9M | -$5.3M | -$14.2M | -$27.6M | -$16.2M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$53.0K | -$111.0K | -$318.0K | $357.0K | $108.0K | |
| Research And Development Expense | $2.4M | $10.7M | ||||
| Operating Expenses | $5.2M | $16.1M | ||||
| Nonoperating Income Expense | $1.7M | $1.9M | ||||
| Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments | $0.00 | $503.0K | ||||
| Income Tax Expense Benefit | $0.00 | $0.00 | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.6M | -$14.2M | ||||
| General And Administrative Expense | $2.8M | $5.4M | ||||
| Comprehensive Income Net Of Tax | -$3.6M | -$14.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | $301.3M | -$94.6M | -$34.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $250.9M | $23.5M | $15.0M |
| Common Stock Value | $3.0K | $1.0K | |
| Write Off Of Deferred Debt Issuance Cost | $0.00 | $3.2M | |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $0.00 | $2.4M | |
| Retained Earnings Accumulated Deficit | -$129.5M | -$104.3M | |
| Restricted Cash Noncurrent | $770.0K | $498.0K | |
| Property Plant And Equipment Net | $1.6M | $1.9M | |
| Prepaid Expense And Other Assets Current | $13.2M | $880.0K | |
| Operating Lease Right Of Use Asset | $2.2M | $2.3M | |
| Operating Lease Liability Noncurrent | $2.8M | $3.2M | |
| Operating Lease Liability Current | $730.0K | $487.0K | |
| Non Cash Lease Expense | $147.0K | $308.0K | |
| Marketable Securities Current | $45.0M | $5.0M | |
| Liabilities Current | $7.4M | $8.1M | |
| Liabilities And Stockholders Equity | $312.9M | $33.5M | |
| Liabilities | $11.6M | $13.8M | |
| Gain Loss On Sale Of Investments | $119.0K | $955.0K | |
| Derivative Liabilities Noncurrent | $1.3M | $2.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $227.5M | $8.5M | |
| Cash And Cash Equivalents At Carrying Value | $250.2M | $23.0M | |
| Assets Current | $308.4M | $28.9M | |
| Assets | $312.9M | $33.5M | |
| Additional Paid In Capital Common Stock | $430.7M | $9.7M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $168.0K | $111.0K | |
| Accrued Liabilities Current | $4.6M | $5.3M | |
| Accretion Amortization Of Discounts And Premiums Investments | -$261.0K | $34.0K | |
| Accounts Payable Current | $2.1M | $2.3M | |
| Temporary Equity Carrying Amount Attributable To Parent | $114.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $310.2M | -$103.9M | -$99.3M | -$91.5M | -$77.4M | -$50.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $270.3M | $15.6M | ||||
| Common Stock Value | ||||||
| Write Off Of Deferred Debt Issuance Cost | ||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | ||||||
| Retained Earnings Accumulated Deficit | -$118.1M | |||||
| Restricted Cash Noncurrent | $512.0K | |||||
| Property Plant And Equipment Net | $1.6M | |||||
| Prepaid Expense And Other Assets Current | $1.9M | |||||
| Operating Lease Right Of Use Asset | $2.2M | |||||
| Operating Lease Liability Noncurrent | $2.9M | |||||
| Operating Lease Liability Current | $730.0K | |||||
| Non Cash Lease Expense | ||||||
| Marketable Securities Current | $44.7M | |||||
| Liabilities Current | $6.6M | |||||
| Liabilities And Stockholders Equity | $320.7M | |||||
| Liabilities | $10.5M | |||||
| Gain Loss On Sale Of Investments | ||||||
| Derivative Liabilities Noncurrent | $942.0K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | ||||||
| Cash And Cash Equivalents At Carrying Value | $269.7M | |||||
| Assets Current | $316.4M | |||||
| Assets | $320.7M | |||||
| Additional Paid In Capital Common Stock | $428.3M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$53.0K | |||||
| Accrued Liabilities Current | $3.3M | |||||
| Accretion Amortization Of Discounts And Premiums Investments | ||||||
| Accounts Payable Current | $2.6M | |||||
| Temporary Equity Carrying Amount Attributable To Parent |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Share Based Compensation | $4.2M | $3.1M |
| Proceeds From Warrant Exercises | $247.0K | $23.0K |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $0.00 | $40.0M |
| Proceeds From Issuance Initial Public Offering | $327.8M | $0.00 |
| Payments To Acquire Property Plant And Equipment | $52.0K | $769.0K |
| Payments To Acquire Marketable Securities | $44.8M | $29.7M |
| Payments Of Stock Issuance Costs | $25.4M | $0.00 |
| Payments Of Debt Issuance Costs | $0.00 | $1.7M |
| Net Cash Provided By Used In Operating Activities | -$35.2M | -$53.1M |
| Net Cash Provided By Used In Investing Activities | -$39.9M | $23.2M |
| Net Cash Provided By Used In Financing Activities | $302.6M | $38.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $12.3M | $1.8M |
| Increase Decrease In Operating Lease Liability | -$134.0K | -$60.0K |
| Increase Decrease In Accrued Interest On Marketable Securities | -$268.0K | $114.0K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$910.0K | $5.0M |
| Proceeds From Sale Of Available For Sale Securities Debt | $2.5M | $23.6M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 8.0M | 358.2K |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 8.0M | 358.2K |
| Earnings Per Share Diluted | $-3.13 | $-176.15 |
| Earnings Per Share Basic | $-3.13 | $-176.15 |
| Common Stock Shares Issued | 25.3M | 251.7K |
| Common Stock Shares Outstanding | 25.3M | 251.7K |
| Common Stock Shares Authorized | 500.0M | 105.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Temporary Equity Shares Outstanding | 78.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 5.8M | 359.1K |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 5.8M | 359.1K |
| Earnings Per Share Diluted | $-0.61 | $-39.49 |
| Earnings Per Share Basic | $-0.61 | $-39.49 |
| Common Stock Shares Issued | ||
| Common Stock Shares Outstanding | 25.3M | |
| Common Stock Shares Authorized | 500.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | |
| Temporary Equity Shares Outstanding |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.2M | $3.1M |
| Investment Income Interest | $3.9M | $1.7M |
| Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | $1.2M | -$947.0K |
| Issuance Of Stock And Warrants For Services Or Claims | $0.00 | $71.0K |
| Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments | 116,100,000.0% | -94,700,000.0% |
| Conversion Of Stock Amount Converted1 | $114.3M | $0.00 |
| Write Off Of Property And Equipment | $8.0K | $0.00 |
| Stock Issued During Period Value Stock Options Exercised | $20.0K | |
| Stock Issued During Period Value New Issues | $302.3M | |
| Stock Issued During Period Value Issued For Services | $71.0K | |
| Stock Issued During Period Value Conversion Of Units | $114.3M | |
| Stock Issued During Period Shares Stock Options Exercised | 6.0K | |
| Stock Issued During Period Shares Stock Options And Warrants Exercised | 247.0K | |
| Stock Issued During Period Shares New Issues | 464.00 | 253.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $881.0K | $335.0K | $634.0K | $472.0K | $204.0K | $137.0K |
| Investment Income Interest | $707.0K | $384.0K | ||||
| Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | $983.0K | $1.0M | ||||
| Issuance Of Stock And Warrants For Services Or Claims | ||||||
| Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments | ||||||
| Conversion Of Stock Amount Converted1 | ||||||
| Write Off Of Property And Equipment | ||||||
| Stock Issued During Period Value Stock Options Exercised | $20.0K | |||||
| Stock Issued During Period Value New Issues | $3.0K | |||||
| Stock Issued During Period Value Issued For Services | $71.0K | |||||
| Stock Issued During Period Value Conversion Of Units | $114.3M | |||||
| Stock Issued During Period Shares Stock Options Exercised | ||||||
| Stock Issued During Period Shares Stock Options And Warrants Exercised | 247.0K | |||||
| Stock Issued During Period Shares New Issues |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.